Navigation Links
Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology
Date:5/21/2010

KYOTO, Japan and MARCY L'ETOILE, France, May 21 /PRNewswire/ -- Shimadzu and bioMerieux announce today that they have entered into a partnership to commercialize a mass spectrometry system for bacterial identification in microbiology laboratories. bioMerieux will work with Shimadzu and their subsidiary, Kratos Analytical, to adapt their linear MALDI-TOF* mass spectrometry technology for optimized integration into the microbiology laboratory workflow. This new solution is planned for commercialization by bioMerieux in 2010, together with the microbial database acquired from AnagnosTec.  

Shimadzu has developed a broad range of technologies, encompassing analytical and measuring instruments, including liquid chromatographs, mass spectrometers, spectrophotometers and life science instruments, across many fields. The company has a long experience in mass spectrometry, including pioneering work in the development of MALDI-TOF mass spectrometry technology.

As the world leader in microbiology, bioMerieux will bring its expertise in infectious diseases and extensive library of microorganisms. The company is constantly expanding its product offering to meet the diverse needs of microbiology labs and this new identification solution will be fully integrated with bioMerieux's VITEK®, the world's leading platform for identification and antibiotic susceptibility testing (AST).

"We are very proud to announce our collaboration with bioMerieux, and we expect to make a significant contribution to the field of bacterial identification as a result," said Osamu Ando, General Manager for Analytical & Measuring Instruments Division at Shimadzu Corporation. "Over the past few years, MALDI-TOF MS has become a key part of our product range, and is driving the expansion of our life science business. This collaboration with bioMerieux represents a new phase in the evolution of our business by expanding it from the research market into diagnostic testing."

"We are very pleased to be partnering with Shimadzu, a leader in mass spectrometry and innovative technologies," said Thierry Bernard, Corporate Vice President, Global Commercial Operations at bioMerieux. "By combining Shimadzu's expertise and our unique understanding of the microbiology laboratory, bioMerieux will be the only company to provide a solution integrating mass spectrometry for bacterial ID with the market's fastest AST on VITEK® 2. This complete offer, including the new Myla™ middleware, clearly demonstrates bioMerieux's commitment to enhance productivity in the lab," he added.

*About Matrix Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry

In MALDI-TOF, the sample to be analyzed is mixed with another compound, called a matrix. The mixture is applied to a metal plate and irradiated with a laser. The matrix absorbs the laser light and vaporizes, along with the sample, in the process gaining an electrical charge (ionization).

Electric fields then guide the ions into the time of flight mass spectrometer which separates them according to 'weight' (mass) and displays the results as a series of lines (spectrum) which correspond to different fragments that have broken away from the original molecule. By analyzing the pattern of fragments it is possible to deduce the structure of the molecule.

The system proposed in this collaboration takes this further by comparing the sample spectrum to a database of spectra from a growing number of bacterial species to allow the system to accurately identify the species in question.

About Shimadzu

Founded in 1875, Shimadzu Corporation, a leader in the development of advanced technologies, has a distinguished history of innovation built on the foundation of contributing to society through science and technology. Shimadzu presently offers a multitude of products, encompassing analytical and measuring instruments, medical systems and equipment, aircraft equipment, and industrial equipment, across a wide range of fields, as well as meticulous, responsive service. They maintain a global network of sales, service, technical support and applications centers on six continents, and have established long-term relationships with a host of highly trained distributors located in over 100 countries.

Other information can be found at www.shimadzu.com.

About bioMerieux

Advancing diagnostics to improve public health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2009, revenues reached euro 1.223 billion with 85% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com


'/>"/>
SOURCE bioMerieux
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. bioMerieux Introduces Surveillance Tool to Fight Healthcare-Associated Infections
2. Laboratory Customers Name bioMerieux Top Of Class for Microbiology
3. ExonHit and bioMerieux Amend Their Strategic Partnership
4. Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venters Creation of Synthetic Life
5. Synthetic Genomics Inc. Applauds the Venter Institutes Work in Creating the First Synthetic Bacterial Cell
6. First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers
7. Drug Safety Firm BioSoteria Receives Women's Business Enterprise Certification
8. Webinar Alert: Managing Paper at Its Roots: Extending Beyond Document Management to Enterprise Content Compliance
9. Elekta / Mitsubishi Electric Collaboration Helps Japans Gunma University Heavy Ion Medical Center Launch Advanced Carbon Ion Therapy for Treating Cancer
10. Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership
11. Professor Sander van Deventer Appointed to Supervisory Board of AMT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, ... with the first pluripotent stem cell-derived islet replacement ... in clinical-stage development, today announced that ViaCyte and ... Companies of Johnson & Johnson, have agreed to ... into ViaCyte.  The agreement provides ViaCyte with an ...
(Date:2/3/2016)... 3, 2016 New Jersey Health Foundation (NJHF) ... million for researchers in New Jersey ... that demonstrates exciting potential.   James ... the New Jersey Health Foundation Research Grant Program ... educational institutions— Princeton University, Rutgers University, Rowan University ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
Breaking Biology News(10 mins):